Literature DB >> 27529610

Measurement of Symptoms Pre- and Post-treatment of Dry Eye Syndromes.

Charles W McMonnies1.   

Abstract

: Valid assessment of dry eye syndrome symptoms is essential for diagnosis and for making treatment decisions and monitoring responses to treatment. Notwithstanding the desirability of being able to measure across several assessment domains to gauge the influence of symptom burden on the quality of life, the time-consuming nature of such assessments may make them unsuitable for routine clinical use. This review of symptom assessment methods examines the relative merits of visual analogue and Likert scales. Also examined are ways in which symptoms can be influenced by comorbid diseases and associated medications, and how the validity of assessing treatment efficacy could be compounded by natural progression of a dry eye syndrome apart from either favorable, neutral, or adverse responses to treatment. Follow-up assessments may also be biased by patient expectations. How validity of responses could be improved by the instructional use of a demonstration scale is described and illustrated. Personal instruction is suggested for patients anticipated to have age- or language-related difficulties but for some patients instruction could be successfully self-directed. A comparison of methods used to monitor dry eye syndrome treatment has allowed recommendations to be made for a method of using visual analogue scales which incorporates features which have been demonstrated to be advantageous in previous studies. The continuous nature of a visual analogue scale allows for smaller changes to be recorded with associated better discriminating capacity. More powerful statistical analysis of findings is possible when using visual analogue scales. Reference to previous assessment scores and exactly the same scale anchors improve the reliability of measurements of change in symptoms over time.

Entities:  

Mesh:

Year:  2016        PMID: 27529610     DOI: 10.1097/OPX.0000000000000965

Source DB:  PubMed          Journal:  Optom Vis Sci        ISSN: 1040-5488            Impact factor:   1.973


  8 in total

1.  Contact Lens Adaption in Neophytes.

Authors:  Andrew D Pucker; Kelsy Steele; Erin Rueff; Quentin X Franklin; Kate McClure; Keyur Savla; Jeffrey J Walline
Journal:  Optom Vis Sci       Date:  2021-03-01       Impact factor: 2.106

Review 2.  Reflections on Dry Eye Syndrome Treatment: Therapeutic Role of Blood Products.

Authors:  Victor J Drew; Ching-Li Tseng; Jerard Seghatchian; Thierry Burnouf
Journal:  Front Med (Lausanne)       Date:  2018-02-23

3.  A Novel Rat Model of Dry Eye Induced by Aerosol Exposure of Particulate Matter.

Authors:  Ning Mu; He Wang; Dongyan Chen; Fan Wang; Ling Ji; Can Zhang; Mingxin Li; Peirong Lu
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-01-03       Impact factor: 4.799

4.  Pain perception description after advanced surface ablation.

Authors:  Eva M Sobas; Sebastián Videla; Amanda Vázquez; Itziar Fernández; Miguel J Maldonado; José-Carlos Pastor
Journal:  Clin Ophthalmol       Date:  2017-04-07

5.  A novel system, TearCare®, for the treatment of the signs and symptoms of dry eye disease.

Authors:  David Badawi
Journal:  Clin Ophthalmol       Date:  2018-04-10

6.  Evaluation of Potential Pain Biomarkers in Saliva and Pain Perception After Corneal Advanced Surface Ablation Surgery.

Authors:  Eva M Sobas; Amanda Vázquez; Sebastián Videla; Roberto Reinoso; Itziar Fernández; Carmen Garcia-Vazquez; Miguel J Maldonado; J Carlos Pastor
Journal:  Clin Ophthalmol       Date:  2020-03-03

7.  A phase I study to evaluate the safety, tolerability, pharmacodynamic and pharmacokinetic profiles of ocular GLH8NDE in healthy male adults.

Authors:  Jihyun Jung; Ki Young Huh; Xuanyou Jin; Ahnul Ha; Ki Ho Park; Jun Sang Park; Eunjung Kim; Jaehwi Lee; In-Jin Jang; Howard Lee
Journal:  Clin Transl Sci       Date:  2021-09-15       Impact factor: 4.689

8.  Corneal Epithelial Stem Cell Supernatant in the Treatment of Severe Dry Eye Disease: A Pilot Study.

Authors:  Sloan W Rush; Jennifer Chain; Hiranmoy Das
Journal:  Clin Ophthalmol       Date:  2021-07-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.